Within the current level of medical technology and medical knowledge, most patients with advanced liver cancer presenting with systemic spread usually have a survival time of less than six months or even less. Because the most common malignant tumor of the liver, namely hepatocellular carcinoma, once distant metastasis occurs, there is no particular treatment method in clinical practice. Very few patients may be able to control the growth of tumor or even obtain long-term survival with tumor through molecular targeted drugs, but most patients are unable to control the growth of tumor. Interventional therapy, radiofrequency therapy or symptomatic treatment are usually used to improve patients’ quality of life and prolong their life span. That is, most patients survive for less than six months or even shorter when there are no specific molecular targeted drugs to control the growth of liver cancer cells.